The Lancet Infectious Diseases, Journal Year: 2024, Volume and Issue: 24(10), P. 1066 - 1067
Published: May 3, 2024
Language: Английский
International Journal of Cancer, Journal Year: 2024, Volume and Issue: 155(4), P. 618 - 626
Published: May 9, 2024
Immunocompromised patients are at high risk to fail clearance of SARS-CoV-2. Prolonged COVID-19 constitutes a health and management problem as cancer treatments often have be disrupted. As SARS-CoV-2 evolves, new variants concern emerged that evade available monoclonal antibodies. Moreover, antiviral therapy promotes escape mutations, particularly in immunocompromised patients. These frequently suffer from prolonged infection. No successful treatment has been established for persistent Here, we report on series 21 with COVID-19-most them hematologic malignancies-treated plasma obtained recently convalescent or vaccinated donors combination thereof. Repeated dosing SARS-CoV-2-antibody-containing could clear infection 16 out even if COVID-19-specific failed induce sustained viral improve clinical course Ten were major responders defined an increase delta(d)Ct > = 5 after the first administration and/or (C/VP). On average, PCR Ct values increased median value 22.55 (IQR 19.10-24.25) 29.57 27.55-34.63; p <.0001) response subgroup. Furthermore, when treated second time C/VP, 4 initial nonresponders showed Ct-values 23.13 17.75-28.05) 32.79 31.75-33.75; .013). Our results suggest C/VP feasible malignancies who did not respond treatment.
Language: Английский
Citations
4
BMC Infectious Diseases, Journal Year: 2025, Volume and Issue: 25(1)
Published: Jan. 27, 2025
COVID-19 remains a complex health challenge. We analysed the characteristics and outcomes of COVID-19-related hospitalisations during JN.1 variant dominance. Conducted in hospital serving socioeconomically deprived population, this study included all adults hospitalised with from 1st November 2023 to 31st August 2024. The primary outcome was in-hospital mortality, relation demographic, clinical, laboratory parameters. Among 122 individuals (median age 76 years, 58.2% males, median comorbidity index 5), 114/122 (93.4%) had received ≥ 1 SARS-CoV-2 vaccination, 23 months elapsed since last dose. Fever (67/122, 54.9%) dyspnoea (49/122, 40.2%) were common presenting symptoms, 78/122 (64%) showing CT evidence pneumonia; 25/122 (20%) purely neurological presentations. Treatment remdesivir (115/122, 94.3%) and/or nirmatrelvir/ritonavir (9/122, 7.4%), sotrovimab (15/122, 12.3%), corticosteroids (61/122, 50.0%), oxygen supplementation (76/122, 62.3%). Whereas 107/122 (87.7%) discharged after seven days, mortality 15/122 (12.3%) 16 days. Baseline factors associated neutrophil-lymphocyte ratio > 8, D-dimer 1800 ng/mL, procalcitonin 1.0 albumin < 3.2 g/dL; admission, nasopharyngeal antigen positivity persisting for 12 hospitalisation 10 higher requirements resulting corticosteroid use, healthcare-associated bacteraemia increased odds mortality. parameters persistent despite antiviral therapy offer readily available prognostic insights patients COVID-19. It is imperative advocate up-to-date vaccination among older people other vulnerable groups.
Language: Английский
Citations
0
BMC Infectious Diseases, Journal Year: 2025, Volume and Issue: 25(1)
Published: April 28, 2025
Immunocompromised (IC) patients face significant challenges in managing COVID-19 due to their heightened susceptibility severe illness, persistent infections, and the potential development of drug resistance. Studies indicate that IC patients, particularly those with hematologic malignancies (HM), hematopoietic stem cell transplants (HSCTR), or solid organ (SOTR), experience higher mortality rates worse outcomes compared general population, even post-vaccination. The persistence virus these combined its rapid mutation, further complicates treatment. Recent evidence supports use neutralizing monoclonal antibodies (mAbs) direct-acting antivirals (DAAs) as a more effective approach viral clearance, reducing mortality, preventing relapses. However, rise resistant variants, especially mAbs, concerns about safety prolonged intensive therapies pose ongoing challenges. Monotherapies often fail short address issues, highlighting need for early therapy (ECT) mAbs DAAs. ECT has shown promise individuals by targeting multiple stages lifecycle, load, clearing infections at earlier stages, which helps mitigate risks disease Continued research is essential refine treatment protocols, evolves. Although studies are needed, current findings suggest may become standard care severely offering better clinical hindering persistence.
Language: Английский
Citations
0
Current Opinion in Infectious Diseases, Journal Year: 2024, Volume and Issue: 37(6), P. 506 - 517
Published: Oct. 23, 2024
Purpose of review The purpose this is to report the available evidence regarding use combination regimens antivirals and/or antibody-based therapy in treatment SARS-CoV-2 immunocompromised patients. Recent findings Literature search identified 24 articles, excluding single case reports, which included mainly patients with hematological malignancies B-cell depletion. Data were divided based on timing and reason for administration treatment, that is, early prevent progression severe COVID-19 prolonged or relapsed infection. We described treated populations, duration composition treatment. briefly addressed new options we proposed an algorithm management infection affected by malignancies. Summary Combination seems effective (73–100%) well tolerated (<5% reported bradycardia, hepatotoxicity, neutropenia) strategy treating prolonged/relapsed infections host, although its optimal cannot be defined currently evidence. role as at a high risk disease/persistent shedding requires further from comparison monotherapy, even though efficacy was combinations plus mAbs previous viral variants.
Language: Английский
Citations
2
Journal of Antimicrobial Chemotherapy, Journal Year: 2024, Volume and Issue: 79(9), P. 2400 - 2402
Published: July 29, 2024
Journal Article Comment on: Suboptimal response to combination therapy with tixagevimab/cilgavimab and remdesivir for persistent SARS-CoV-2 infections in immunocompromised patients Get access Federico Barone, Barone Dipartimento di Scienze Biomediche e Cliniche, Università degli Studi Milano, Milan, ItalyIII Infectious Diseases Unit, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Italy Search other works by this author Oxford Academic PubMed Google Scholar Andrea Giacomelli, Giacomelli Corresponding author. E-mails: [email protected]; [email protected] https://orcid.org/0000-0003-3685-4289 Giacomo Casalini, Casalini III Mario Corbellino, Corbellino Alessia Lai, Lai https://orcid.org/0000-0002-3174-5721 Gori, Gori ItalyII ItalyCentre Multidisciplinary Research Health Science (MACH), Spinello Antinori https://orcid.org/0000-0003-0569-9407 of Antimicrobial Chemotherapy, dkae234, https://doi.org/10.1093/jac/dkae234 Published: 29 July 2024
Language: Английский
Citations
1
Methods in molecular biology, Journal Year: 2024, Volume and Issue: unknown, P. 189 - 197
Published: Aug. 27, 2024
Language: Английский
Citations
1
Mediterranean Journal of Hematology and Infectious Diseases, Journal Year: 2024, Volume and Issue: 16(1), P. e2024043 - e2024043
Published: April 30, 2024
Abstract: Im We describe here a single-center case series of 27 IC COVID-19 inpatients (mostly with haematological disorders) treated combined therapy based on tixagevimab/cilgavimab (T/C) plus small-molecule antivirals (AV), between April 1 2022 and November 30 2022. Keywords: immunocompromised; SARS-CoV-2 infection; monoclonal antibodies; antivirals; persistent viral evolution
Language: Английский
Citations
1
BioMed Research International, Journal Year: 2024, Volume and Issue: 2024(1)
Published: Jan. 1, 2024
Despite the potential of neutralizing antibodies in management severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2), clinical research on its efficacy Chinese patients remains limited. This study is aimed at investigating therapeutic effect combination antiviral therapy with monoclonal for recurrent persistent SARS‐CoV‐2 pneumonia lymphoma complicated by B cell depletion. A prospective was conducted who were treated nirmatrelvir/ritonavir and antibody tixagevimab–cilgavimab (tix‐cil). The primary outcome rate infection. Five experienced received tix‐cil treatment. All had a history CD20 use within year preceding infection, two also Bruton’s tyrosine kinase (BTK) inhibitor use. These notably low lymphocyte counts exhibited near depletion cells. five tested negative serum IgG IgM antibodies. None developed reinfection after treatment during 6‐month follow‐up period. In conclusion, administration SARS‐CoV‐2‐neutralizing showed encouraging against depletion, along preventive up to 6 months.
Language: Английский
Citations
0
The Lancet Infectious Diseases, Journal Year: 2024, Volume and Issue: 24(10), P. 1066 - 1067
Published: May 3, 2024
Language: Английский
Citations
0